Soma S. Nag, PhD

Characteristics and Treatment of Adult Patients With Post-Traumatic Stress Disorder – A Retrospective Claims-Based Analysis

Abstract: Background: Despite available guidelines, identifying and managing post-traumatic stress disorder (PTSD) in clinical practice remains challenging due to the heterogenous disease...

Soma S. Nag , PhD;

Jessica Maitland ;

01/19/2023

Dosing Intervals and Cost Per Day of Aripiprazole Once-Monthly 400 mg and Aripiprazole Lauroxil 882 mg in the Treatment of Patients With Schizophrenia or Bipolar I Disorder

Abstract: This model examined annual drug treatment costs for aripiprazole once-monthly (AOM) 400 mg and aripiprazole lauroxil (AL) 882 mg among adult patients with schizophrenia or bipol...

Soma S. Nag , PhD;

01/19/2023

Cost-Effectiveness of Aripiprazole 2-Month Ready-to-Use 960 mg Long-Acting Injectable for the Treatment of Patients With Schizophrenia

Abstract: Background: Aripiprazole 2-month Ready to Use 960 mg (ARI 2M RTU) is a long-acting injectable antipsychotic (LAI) in development for treatment of schizophrenia and maintenance t...

Soma S. Nag , PhD;

Svenja Petersohn ;

01/19/2023

Dosing Intervals and Cost Per Day of Aripiprazole Once Every Month 400 mg and Aripiprazole Lauroxil 882 mg in the Treatment of Patients Diagnosed with Schizophrenia or Bipolar I Disorder

An updated claims database analysis of two formulations of the LAI aripiprazole, to evaluate the benefit of different dosing intervals to optimize the annual drug treatment costs among pa...

Soma S. Nag , PhD;

10/26/2023